141 related articles for article (PubMed ID: 2499251)
1. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
Antimicrob Agents Chemother; 1989 Apr; 33(4):519-21. PubMed ID: 2499251
[TBL] [Abstract][Full Text] [Related]
2. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
Antimicrob Agents Chemother; 1991 Aug; 35(8):1547-50. PubMed ID: 1929325
[TBL] [Abstract][Full Text] [Related]
3. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
Kaatz GW; Barriere SL; Schaberg DR; Fekety R
Antimicrob Agents Chemother; 1987 Apr; 31(4):527-30. PubMed ID: 3649202
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
Antimicrob Agents Chemother; 1990 Feb; 34(2):257-60. PubMed ID: 2327773
[TBL] [Abstract][Full Text] [Related]
5. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Lamp KC; Bailey EM; Rybak MJ
Antimicrob Agents Chemother; 1992 Jun; 36(6):1192-7. PubMed ID: 1329613
[TBL] [Abstract][Full Text] [Related]
6. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis.
Kaatz GW; Barriere SL; Schaberg DR; Fekety R
J Antimicrob Chemother; 1987 Nov; 20(5):753-8. PubMed ID: 3429376
[TBL] [Abstract][Full Text] [Related]
7. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.
Lucet JC; Herrmann M; Rohner P; Auckenthaler R; Waldvogel FA; Lew DP
Antimicrob Agents Chemother; 1990 Dec; 34(12):2312-7. PubMed ID: 2128441
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.
Carpenter TC; Hackbarth CJ; Chambers HF; Sande MA
Antimicrob Agents Chemother; 1986 Sep; 30(3):382-4. PubMed ID: 3640590
[TBL] [Abstract][Full Text] [Related]
9. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.
Fernandez-Guerrero M; Rouse M; Henry N; Wilson W
Antimicrob Agents Chemother; 1988 May; 32(5):747-51. PubMed ID: 3164989
[TBL] [Abstract][Full Text] [Related]
10. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro.
Chambers HF; Hackbarth CJ; Drake TA; Rusnak MG; Sande MA
J Infect Dis; 1984 Jun; 149(6):894-903. PubMed ID: 6564133
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Aeschlimann JR; Houlihan HH; Mercier RC; Rybak MJ
Antimicrob Agents Chemother; 1998 Apr; 42(4):981-3. PubMed ID: 9559828
[TBL] [Abstract][Full Text] [Related]
12. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.
Chambers HF; Sande MA
Antimicrob Agents Chemother; 1984 Jul; 26(1):61-4. PubMed ID: 6236747
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
Kim YS; Liu Q; Chow LL; Chambers HF; Täuber MG
Antimicrob Agents Chemother; 1998 Dec; 42(12):3325-7. PubMed ID: 9835540
[TBL] [Abstract][Full Text] [Related]
14. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis.
Rouse MS; Wilcox RM; Henry NK; Steckelberg JM; Wilson WR
Antimicrob Agents Chemother; 1990 Feb; 34(2):273-6. PubMed ID: 2327776
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
Antimicrob Agents Chemother; 1989 Aug; 33(8):1184-7. PubMed ID: 2802547
[TBL] [Abstract][Full Text] [Related]
16. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ciprofloxacin in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis caused by a cloxacillin-tolerant strain and its non-tolerant variant.
Voorn GP; Thompson J; Goessens WH; Schmal-Bauer WC; Broeders PH; Michel MF
J Antimicrob Chemother; 1994 Apr; 33(4):785-94. PubMed ID: 8056697
[TBL] [Abstract][Full Text] [Related]
18. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.
Gilbert M; Boscia JA; Kobasa WD; Kaye D
Antimicrob Agents Chemother; 1986 Mar; 29(3):461-3. PubMed ID: 3459391
[TBL] [Abstract][Full Text] [Related]
19. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus.
Nicolau DP; Freeman CD; Nightingale CH; Coe CJ; Quintiliani R
Antimicrob Agents Chemother; 1994 Jul; 38(7):1515-8. PubMed ID: 7979281
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Aeschlimann JR; Houlihan HH; Mercier RC; Rybak MJ
Antimicrob Agents Chemother; 1998 Feb; 42(2):254-6. PubMed ID: 9527768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
